## SUPPLEMENTARY TABLES

**Supplementary Table S1.** Risk of bias assessment

| **Jastreboff 2022 [4]** | **Risk of bias** | **Author Judgement** |
|---|---|---|
| Random sequence generation (selection bias) | Low risk | Randomized, placebo-controlled trial |
| Allocation concealment (selection bias) | Low risk | Participants were randomly assigned in a 1:1:1:1 ratio to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or placebo |
| Blinding of participants & personnel (performance bias) | Low risk | Double-blind trial |
| Blinding of outcome assessment (detection bias) | Low risk | Double-blind trial |
| Incomplete outcome data (attrition bias) | Low risk | Overall, 86.0% of participants completed the primary trial treatment period. Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (reporting bias) | Low risk | All pre-specified outcomes are reported. |
| Other biases | High risk | Funding for this study was provided by was funded by Eli Lilly, Indianapolis. Five of authors are employees of the pharmaceutical company. |
| **Wadden 2023 [5]** | **Risk of bias** | **Author Judgement** |
| Random sequence generation (selection bias) | Low risk | Randomized, placebo-controlled trial |
| Allocation concealment (selection bias) | Low risk | Participants were randomly assigned in a 1:1 ratio to receive either the maximum tolerated dose of tirzepatide (10 or 15 mg) or placebo. Assignment to treatment group was determined by a computer-generated random sequence using a validated interactive web-response system. |
| Blinding of participants & personnel (performance bias) | Low risk | Double-blind trial |
| Blinding of outcome assessment (detection bias) | Low risk | Double-blind trial |
| Incomplete outcome data (attrition bias) | Low risk | Of the 579 randomized participants, 479 (82.7%) completed the study. Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups. |
| Selective reporting (reporting bias) | Low risk | All pre-specified outcomes are reported. |
| Other biases | High risk | Funding for this study was provided by was funded by Eli Lilly, Indianapolis. Five of authors are employees of the pharmaceutical company. |